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Abstract. The World Health Organization currently recommends annual mass antibiotic treatment to eliminate the
ocular chlamydia that cause blinding trachoma. Active trachoma is believed to be seasonal in many areas of the world,
and the optimal season in which to treat has not as yet been established. Here we use mathematical models of disease
transmission to demonstrate that ideally, treatment should be administered before the low season to have the greatest
chance of locally eliminating infection.
INTRODUCTION
Trachoma is the leading cause of infectious blindness
worldwide. Although it has disappeared throughout much of
the world, it still affects more than 150 million people in
developing countries.1 The World Health Organization
(WHO), along with non-governmental organizations and
public health services, has launched a major initiative to elimi-
nate the disease.2 A key element in this effort has been the
annual mass administration of systemic antibiotics. Since it is
difficult to identify which individuals harbor the ocular chla-
mydial infection that causes trachoma, antibiotics are often
distributed simultaneously to an entire community. Mass dis-
tribution of azithromycin has been surprisingly successful in
reducing infection.3,4 However, the seasonal timing of treat-
ments has not been addressed. In this study, we use math-
ematical models of trachoma transmission to determine which
season annual mass antibiotic treatments should be adminis-
tered to most effectively eliminate trachoma.
METHODS
We model the prevalence of ocular chlamydial infection in
a community over time in two different ways: with differential
equations, where the results at any time-point are completely
dependent on the results at previous time-points (determin-
istic transmission model), and with simulations, where the
effects of chance are also included (stochastic transmission
model).
Deterministic transmission model. The transmission of
ocular chlamydia within a community can be described by
the nonlinear ordinary differential equation shown in Equa-
tion 1.5
dP
dt
= 1 − PP − P (1)
The prevalence, P, changes over time, t, at a rate equal to
the rate of new infections minus the rate of recovery from
existing infections. The rate of new infections is dependent on
the rate of contact between individuals that can result in
transmission () and the probability that one of the two in-
dividuals who meet is susceptible (1 - P) and the other infec-
tious (P). A decrease in prevalence occurs when an infected
individual recovers (at a rate ) and depends on the preva-
lence of infected individuals. We assume that ocular chlamyd-
ial infection does not affect mortality. The general solution
for this differential equation is a logistic equation.5
Annual treatment is modeled by decreasing the prevalence
by an amount equal to the treatment coverage of the popu-
lation times the efficacy of the antibiotic in an individual.6 We
assume an average efficacy of 95% based on studies of mac-
rolides in ocular and genital infections.6 While 60−95% cov-
erage has been achieved in various settings, we use an average
coverage of 80%, the target of the WHO for treatment pro-
grams.3,7,8 We set values of  and  to be 0.2 and 0.1 per
month respectively, consistent with infection returning post-
treatment at an exponential rate of 10% per month, the rate
found empirically in a recent study of 24 Ethiopian villages.4
Seasonal effects. To model a seasonal effect, the transmis-
sion parameter () is varied over time so that the equilibrium
prevalence fluctuates in a sinusoidal manner over a year.
Equation 2 shows the resulting modified transmission param-
eter, , with its phase determined by an offset measured in
months.
 =  1 + cos 2 t + monthly offset12  (2)
Stochastic transmission model. Since a deterministic model
does not account for the chance effects that may result in local
extinction or fadeout of infection in small communities,9 we
also perform simulations with a stochastic model using the
same parameters as the deterministic model. We assume an
effective community size of 100 individuals because there are
approximately 100 children  10 years old per community in
previously studied trachoma-endemic areas of Ethiopia, the
age group that carries the greatest burden of infection.4 Using
standard event-driven simulation techniques,10 the rates at
which individuals become infected or recover from infection
(i.e., disease state changes) are used to determine the time
between such events occurring to individuals within the vil-
lage.11,12 When the next stochastic event for a village would
not occur until after the next scheduled periodic treatment,
we simulate the institution of treatment, and then compute
the times of further stochastic events representing disease
state changes for individuals in the village using the post-
treatment parameter values. Results from 5 sets of 2,000
simulated communities were tabulated at 8 evenly spaced
times of the year. The time it took to achieve elimination in
75%, 90%, or 95% of the villages was determined.
RESULTS
The deterministic model shows that the repeated adminis-
tration of antibiotics can progressively reduce infection so
that it approaches elimination, given adequate antibiotic ef-
ficacy and coverage. The effect of treatment without season-
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ality is depicted by the gray shading in Figure 1. Prior to
treatment, the prevalence of infection in the deterministic
seasonal effect model fluctuates between approximately 40%
and 60%. Similarly, the prevalence continues to fluctuate af-
ter treatments, depending on the timing of treatment. Figure
1 shows the course of infection with rounds of annual treat-
ment starting at four evenly spaced times of year. The two
curves in Figure 1A display the prevalence of infection if
annual treatment were to be given three months before the
high season or three months before the low season. Figure 1B
shows the effect of treating at the peak of the high season or
the peak of the low season.
For the stochastic model, the average pre-treatment preva-
lence fluctuates over the year as depicted by the gray shading
in Figure 2. Treating three months before the low season
results in elimination in the shortest period of time. Treating
three months before the high season is the least effective. This
seasonal pattern is found whether we monitor the length of
time for elimination in 75%, 90%, or 95% of the communities
(Figure 2). The 95% confidence interval for the average time
until elimination in a certain percentage of villages at any
time-point ranged from ±2 months to ±5 months.
A sensitivity analysis was performed by adjusting treatment
coverage by ±10%, transmission parameters by ±50%, and
the amplitude of seasonality by ±50%. These scenarios re-
sulted in different times for infection to be eliminated in vil-
lages. However, the minimum duration of treatment required
to eliminate infection in 75%, 90%, or 95% of the villages was
still found at the same time-point: three months before the
trough of the low season.
DISCUSSION
The prevalence of trachoma has been shown to vary by
season in many areas of the world, including Morocco, Tuni-
sia, Egypt, and Nepal.7,13,14 This may be due to the fluctuation
in fly density or water availability because flies are thought to
contribute to transmission and better hygiene may decrease
transmission.15 Currently, it is not clear whether the annual
mass antibiotic treatments recommended by the WHO would
best be administered in the high season or the low season.
One relatively short-term study in Nepal randomized six vil-
lages to treatment in the spring or the fall; in this area, a
seasonal effect was identified, and the clinical prevalence of
trachoma was 20% higher in the spring (P < 0.001). No sig-
nificant difference in treatment season was found one year
after treatment (P  0.61).16 However this study had the
power only to detect a relatively large effect and only com-
pared treatments given at two times of the year. Further em-
pirical studies have not been performed, in part due to the
high cost of monitoring a larger number of villages at multiple
points in the year.
Here, we used mathematical models to evaluate the opti-
mal time of the year to perform mass antibiotic treatments. A
deterministic model suggests that the time course of infection
returning into a community would be different within a year
depending on the treatment season (Figure 1). However,
FIGURE 1. Results from a deterministic seasonal model of tra-
choma transmission. Parameters include 95% antibiotic efficacy, 80%
treatment coverage, exponential infectious rate of 10% per month,
and average pre-treatment prevalence of 50%. Prevalence is shown
without a seasonal effect for comparison (gray shading). A, Treat-
ment is repeated annually three months before the low season (black
line) or three months before the high season (gray line). B, Treatment
is repeated annually at the peak of the high season (black line) or at
the trough of the low season (gray line).
Figure 2. Results from a stochastic seasonal model of trachoma
transmission. Prevalence by season prior to the first annual treatment
(gray shading). Treatment duration as the time to elimination of
infection in 95% (black line), 90% (dark gray line), and 75% (light
gray line) of communities based on the averages of five sets of 2000
simulations at eight treatment time points (circles). Parameters in-
clude an average 95% antibiotic efficacy, 80% treatment coverage,
exponential infectious rate of 10% per month, average pre-treatment
prevalence of 50%, and simulations of an effective population size of
100 individuals per village.
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there are no clear year-to-year differences, even with a rela-
tively strong seasonal effect. Unlike deterministic models, sto-
chastic models can explicitly account for chance effects and
the local elimination of infection in a community. Stochastic
simulations demonstrate that the optimal time to treat to
eliminate infection in a community is three months before the
trough of the low season (three months after the peak of the
high season; Figure 2). This represents the time when trans-
mission rates are the lowest and offers the highest probability
of local elimination in communities of limited population
sizes.
Even if the ideal time to treat is before the low season, it
should be recognized that other considerations may play a
greater role. For example in some areas, this time point may
fall during seasons when access to remote villages may not be
feasible, for example, during the monsoon. It may also be
hard to attain high treatment coverage due to social reasons
such as religious events and festivals. Furthermore, programs
may not be able to concentrate all of their distribution efforts
into a few critical months of the year. Since it is difficult to
determine precisely when the high and low season actually
occur, it may be difficult to structure a program with the
necessary precision to take advantage of the effect observed
in this study. However, mathematical models suggest that,
other things being equal, we increase the probability of locally
eliminating infection by treating after the high season and
before the low season. Mathematical models may be of par-
ticular use in cases such as this where large-scale clinical trials
will likely never be performed.
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